Literature DB >> 33527720

Generalizability of findings from a clinical sample to a community-based sample: A comparison of ADNI and ARIC.

Kan Z Gianattasio1, Erin E Bennett1, Jingkai Wei1, Megha L Mehrotra2, Thomas Mosley3, Rebecca F Gottesman4, Dean F Wong5, Elizabeth A Stuart6, Michael E Griswold7, David Couper8, M Maria Glymour2, Melinda C Power1.   

Abstract

INTRODUCTION: Clinic-based study samples, including the Alzheimer's Disease Neuroimaging Initiative (ADNI), offer rich data, but findings may not generalize to community-based settings. We compared associations in ADNI to those in the Atherosclerosis Risk in Communities (ARIC) study to assess generalizability across the two settings.
METHODS: We estimated cohort-specific associations among risk factors, cognitive test scores, and neuroimaging outcomes to identify and quantify the extent of significant and substantively meaningful differences in associations between cohorts. We explored whether using more homogenous samples improved comparability in effect estimates.
RESULTS: The proportion of associations that differed significantly between cohorts ranged from 27% to 34% across sample subsets. Many differences were substantively meaningful (e.g., odds ratios [OR] for apolipoprotein E ε4 on amyloid positivity in ARIC: OR = 2.8, in ADNI: OR = 8.6). DISCUSSION: A higher proportion of associations differed significantly and substantively than would be expected by chance. Findings in clinical samples should be confirmed in more representative samples.
© 2021 the Alzheimer's Association.

Entities:  

Keywords:  Alzheimer's Disease Neuroimaging Initiative; Alzheimer's disease; Atherosclerosis Risk in Communities; dementia; generalizability

Mesh:

Substances:

Year:  2021        PMID: 33527720      PMCID: PMC8359773          DOI: 10.1002/alz.12293

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   16.655


  38 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

Review 2.  Integrating ADNI results into Alzheimer's disease drug development programs.

Authors:  Jeffrey L Cummings
Journal:  Neurobiol Aging       Date:  2010-05-05       Impact factor: 4.673

3.  In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).

Authors:  Dean F Wong; Paul B Rosenberg; Yun Zhou; Anil Kumar; Vanessa Raymont; Hayden T Ravert; Robert F Dannals; Ayon Nandi; James R Brasić; Weiguo Ye; John Hilton; Constantine Lyketsos; Hank F Kung; Abhinay D Joshi; Daniel M Skovronsky; Michael J Pontecorvo
Journal:  J Nucl Med       Date:  2010-06       Impact factor: 10.057

4.  Vascular imaging abnormalities and cognition: mediation by cortical volume in nondemented individuals: atherosclerosis risk in communities-neurocognitive study.

Authors:  David S Knopman; Michael E Griswold; Seth T Lirette; Rebecca F Gottesman; Kejal Kantarci; A Richey Sharrett; Clifford R Jack; Jonathan Graff-Radford; Andrea L C Schneider; B Gwen Windham; Laura H Coker; Marilyn S Albert; Thomas H Mosley
Journal:  Stroke       Date:  2015-01-06       Impact factor: 7.914

5.  Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods.

Authors:  Susan M Landau; Christopher Breault; Abhinay D Joshi; Michael Pontecorvo; Chester A Mathis; William J Jagust; Mark A Mintun
Journal:  J Nucl Med       Date:  2012-11-19       Impact factor: 10.057

6.  Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort.

Authors:  Rebecca F Gottesman; Marilyn S Albert; Alvaro Alonso; Laura H Coker; Josef Coresh; Sonia M Davis; Jennifer A Deal; Guy M McKhann; Thomas H Mosley; A Richey Sharrett; Andrea L C Schneider; B Gwen Windham; Lisa M Wruck; David S Knopman
Journal:  JAMA Neurol       Date:  2017-10-01       Impact factor: 18.302

Review 7.  Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.

Authors:  Dallas P Veitch; Michael W Weiner; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski
Journal:  Alzheimers Dement       Date:  2018-10-13       Impact factor: 21.566

8.  Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis.

Authors:  Rik Ossenkoppele; Willemijn J Jansen; Gil D Rabinovici; Dirk L Knol; Wiesje M van der Flier; Bart N M van Berckel; Philip Scheltens; Pieter Jelle Visser; Sander C J Verfaillie; Marissa D Zwan; Sofie M Adriaanse; Adriaan A Lammertsma; Frederik Barkhof; William J Jagust; Bruce L Miller; Howard J Rosen; Susan M Landau; Victor L Villemagne; Christopher C Rowe; Dong Y Lee; Duk L Na; Sang W Seo; Marie Sarazin; Catherine M Roe; Osama Sabri; Henryk Barthel; Norman Koglin; John Hodges; Cristian E Leyton; Rik Vandenberghe; Koen van Laere; Alexander Drzezga; Stefan Forster; Timo Grimmer; Pascual Sánchez-Juan; Jose M Carril; Vincent Mok; Vincent Camus; William E Klunk; Ann D Cohen; Philipp T Meyer; Sabine Hellwig; Andrew Newberg; Kristian S Frederiksen; Adam S Fleisher; Mark A Mintun; David A Wolk; Agneta Nordberg; Juha O Rinne; Gaël Chételat; Alberto Lleo; Rafael Blesa; Juan Fortea; Karine Madsen; Karen M Rodrigue; David J Brooks
Journal:  JAMA       Date:  2015-05-19       Impact factor: 56.272

9.  Association of plasma beta-amyloid level and cognitive reserve with subsequent cognitive decline.

Authors:  Kristine Yaffe; Andrea Weston; Neill R Graff-Radford; Suzanne Satterfield; Eleanor M Simonsick; Steven G Younkin; Linda H Younkin; Lewis Kuller; Hilsa N Ayonayon; Jingzhong Ding; Tamara B Harris
Journal:  JAMA       Date:  2011-01-19       Impact factor: 56.272

10.  Rate of cognitive decline in preclinical Alzheimer's disease: the role of comorbidity.

Authors:  Lars Bäckman; Sari Jones; Brent J Small; Hedda Agüero-Torres; Laura Fratiglioni
Journal:  J Gerontol B Psychol Sci Soc Sci       Date:  2003-07       Impact factor: 4.077

View more
  2 in total

1.  Evaluation of the Cost-effectiveness of Drug Treatment for Alzheimer Disease in a Simulation Model That Includes Caregiver and Societal Factors.

Authors:  Kouta Ito; Rick Chapman; Steven D Pearson; Ali Tafazzoli; Kristine Yaffe; Jerry H Gurwitz
Journal:  JAMA Netw Open       Date:  2021-10-01

2.  Self-reported word-finding complaints are associated with cerebrospinal fluid amyloid beta and atrophy in cognitively normal older adults.

Authors:  Maxime Montembeault; Stefan Stijelja; Simona M Brambati
Journal:  Alzheimers Dement (Amst)       Date:  2022-02-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.